13-valent pneumococcal conjugate vaccine

Phase 3Completed

0 watching 0 views this week📈 Rising

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

13-valent Pneumococcal Vaccine

Conditions

13-valent Pneumococcal Vaccine, Immunization, Safety, Antibody Response

Trial Timeline

Apr 1, 2010 → Nov 1, 2010

NCT ID

NCT01026038

About 13-valent pneumococcal conjugate vaccine

13-valent pneumococcal conjugate vaccine is a phase 3 stage product being developed by Pfizer for 13-valent Pneumococcal Vaccine. The current trial status is completed. This product is registered under clinical trial identifier NCT01026038. Target conditions include 13-valent Pneumococcal Vaccine, Immunization, Safety.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (10)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05329259	Approved	Completed	Oct 6, 2022	Nov 30, 2022	Pneumococcal Disease
NCT03571607	Phase 3	Completed	Jul 12, 2018	Nov 16, 2018	Pneumococcal Infections
NCT02034877	Approved	Completed	Aug 1, 2014	Jul 1, 2015	Prevention of Pneumonia and Invasive Disease Caused by the Serotypes in 13vPnC
NCT01026038	Phase 3	Completed	Apr 1, 2010	Nov 1, 2010	13-valent Pneumococcal Vaccine
NCT00963235	Phase 3	Completed	Nov 1, 2009	May 1, 2012	HIV Infections
NCT00708682	Phase 3	Completed	Jul 1, 2008	May 1, 2010	Vaccines, Pneumococcal
NCT00500357	Phase 3	Completed	Nov 1, 2007	Jan 1, 2010	Vaccines, Pneumococcal Conjugate Vaccine
NCT00452452	Phase 3	Completed	Jul 1, 2007	Mar 1, 2008	Pneumococcal Infections
NCT00464945	Phase 3	Completed	Jun 1, 2007	Sep 1, 2008	Pneumococcal Vaccines
NCT00269672	Phase 2	Completed	Sep 1, 2005	Feb 1, 2007	Vaccines, Pneumococcal Conjugate Vaccine

Competing Products

1 competing product in 13-valent Pneumococcal Vaccine

See all competitors

Product	Company	Stage	Hype Score
13-valent pneumococcal conjugate vaccine + 13-valent pneumococcal conjugate vaccine	Pfizer	Approved	84

Other Products from Pfizer